Search PubMed⌕ Search

Biomedical subjects

B M Ansell

Publications and source records attributed to B M Ansell.

At least 163 records · Page 9Linked to original sources
PubMed1976

Naproxen in rheumatoid arthritis. Extended trial.

121 patients with active rheumatoid arthritis, 91 of whom had proved intolerant of other nonsteroidal anti-inflammatory agents, were treated for a mean of 10 months with naproxen. A dosage of 250 mg twice daily produced sustained improvement in most of the standard clinical measurements. 28 patients complained of side effects, with a lower than expected incidence of gastrointestinal complaints and no drug-induced rash being recorded. 19 patients withdrew from the trial because of side effects, while a further 22 withdrew because the drug was ineffective. Naproxen is a useful drug for long-term use in patients with rheumatoid arthritis, including those who have proved intolerant of or experienced inadequate symptomatic relief from other nonsteriodal anti-inflammatory agents.

Adult↗
PubMed1976

Psyche and rheuma.

The paper is based on discussions which took place in a seminar at the European League against Rheumatism Meeting in Helsinki in 1975. The importance of assessing the emotional response in rheumatoid disease, as well as the disease process, is stressed. It is important to consider the effect of the discovery by the patient that severe disease is present. Considerable support by general practitioners and consultants may be necessary at this time. There has been much discussion as to whether patients suffering from rheumatoid arthritis have a different type of personality than other subjects. The evidence is not convincing. The role of stress in the aetiology of rheumatoid arthritis is not properly understood. Anxiolytic and antidepressant drugs may help patients to overcome the anxiety and depression associated with rheumatoid arthritis. Children suffering from the disease present a special problem. The incapacity and isolation, especially in old age, which osteo-arthritis brings may lead to depression and antidepressant therapy is often required. When rheumatic pain seems out of proportion to the physical findings, psychogenic rheumatism should be considered. Rheumatic pains occur in masked depression and low backache may be a depressive equivalent. Pain may be used by some patients to communicate distress.

Aged↗
PubMed1975

Nerve entrapment at the elbow in rheumatoid arthritis.

Although there was some delay in the posterior interosseous branch of the radial nerve conduction time in six of the 152 rheumatoid elbows, in no case were there clinical signs attributable to entrapment of this nerve. Some delay in ulnar nerve conduction was recorded in 27 of the 152 elbows; this was marked in 12. These patients tended to be older and to have more severe disease of the elbow.

Arthritis, Rheumatoid↗
PubMed1975

Effect of penicillamine therapy on circulating immune complexes in rheumatoid arthritis.

The sera of 40 patients with severe progressive rheumatoid arthritis were examined for the presence of soluble immune complexes before penicillamine therapy was started, and again after treatment for a mean period of 14-4 months. The methods used were radiobioassay (macrophage uptake), C1q-binding capacity, and precipitation by 4% polyethylene glycol. Before treatment the sera of 37 patients showed significantly enhanced uptake of 125I-labelled aggregated human IgG by guinea pig macrophages. Treatment produced significant falls in mean erythrocyte sedimentation rate, differential agglutination titre, and serum IgG and IgM levels, and enhancing complexes (EC) decreased or disappeared in 20 patients. In 9 patients EC changed to inhibiting complexes, and in 8 EC levels were unchanged. In 6 of 8 patients with cutaneous vasculitis initially, both lesions and EC disappeared. The total protein and the IgG and IgM precipitated from patients' sera by 4% polyethylene glycol fell significantly on treatment. Antinuclear antibody titres were unchanged by penicillamine, and 3 patients acquired these antibodies during treatment. These findings suggest that penicillamine treatment in rheumatoid arthritis reduces the level of circulating soluble immune complexes in which IgM rheumatoid factor is a component.

Adult↗
PubMed1975

Effect of penicillamine treatment on immune complexes in two cases of seropositive juvenile rheumatoid arthritis.

A correlation has previously been observed between the presence of enhancing complexes and cutaneous vasculitis in rheumatoid arthritis. Two parients with seropositive juvenile rheumatoid arthritis are described in whom enhancing complexes were detected before the appearance of cutaneous vasculitis. Their contrasting response to penicillamine is discussed in relation to the role of of rheumatoid factor and antinuclear antibodies.

Adolescent↗
PubMed1975

Naproxen absorption in children.

A study was carried out in 9 children (mean age 10.8 years) suffering from rheumatic disorders to determine peak plasma levels and plasma curve of naproxen following the administration of a single oral dose of a suspension formulation. The results suggest that there is no significant difference in naproxen peak blood levels and half-life between adults and children and a twice-daily dosage regime, as in adults, should be suitable, therefore, for therapeutic use in children. The formulation was well-tolerated and no untoward effects were noted.

Administration, Oral↗
PubMed1975

The value of tests for antibodies to DNA in monitoring the clinical course of SLE. A long-term study using the Farr test and the DNA counterimmunoelectrophoretic method.

Serial serum samples from fifteen patients with SLE, taken over periods varying from 6 months to 6 years, were tested for DNA binding capacity, DNA electroprecipitins (DNA-EP) and C'3 level to assess the value of these investigations in reflecting clinical disease activity. Patients with renal involvement showed a good correlation between high levels of DNA binding, low serum C'3 and disease activity and typically, their DNA-EP was negative. By contrast, patients without renal involvement in whom vasculitis was prominent, showed a poor correlation of DNA binding capacity to changes in the state of their disease although the DNA-EP test was persistently positive. It was also apparent that both the DNA-BC and C'3 can show marked variation in response to alterations in treatment without accompanying clinical change. Although these serological tests, particularly the DNA binding capacity are of recognized value in the diagnosis of SLE, they serve most usefully as guides to long-term management when they can be related to the clinical pattern of the disease.

Antibodies↗
PubMed1974

Benorylate in management of Still's disease.

The present recommended dose of benorylate is not satisfactory for the management of children suffering from inflammatory polyarthritis. A starting dose of 200 mg/kg/day should be used, and the salicylate level checked at seven days and the dosage adjusted to give an anti-inflammatory effect-that is, a blood salicylate level of between 25 and 30 mg/100 ml. Once a satisfactory level has been achieved, this dosage should be maintained with occasional monitoring of the salicylate level. The paracetamol level does not need to be estimated as it tends to follow the salicylate level, provided that liver function is normal; thus it is quite safe to monitor only the salicylate level. Given in an adequate dosage, benorylate seems to be an acceptable salicylate preparation for use in juveniles suffering from chronic polyarthritis.

Acetaminophen↗